Elecsys® Phospho-Tau (181P) CSF

Robust and accurate biomarker tests to solve clinical questions
Elecsys® Phospho-Tau (181P) CSF

Robust and accurate biomarker tests to solve clinical questions

Elecsys® Phospho-Tau (181P) CSF (pTau) is an in vitro diagnostic immunoassay intended for the quantitative determination of the phosphorylated tau protein concentration in human cerebrospinal fluid (CSF).1

Elecsys® pTau assay is part of the Elecsys® AD portfolio, along with Elecsys® β-Amyloid(1-42) CSF II (AB42 2)  and Elecsys® Total-Tau CSF (tTau) immunoassays.1

Elecsys® AD CSF assays can detect amyloid positivity, enhancing diagnostic accuracy and physician confidence.2,3

Elecsys® AD CSF assays enable timely intervention by identifying patients with MCI at risk of progression to AD.1,3

Related portfolios

Related Instruments

KONTAKTA OSS
HCPs at computer

The Power of Elecsys® in Alzheimer’s disease

Robust, clinically validated results to help ensure patients get the care they deserve

Elecsys® Phospho-Tau (181P) CSF test characteristics

  • Testing time

    18 minutes

  • Test principle

    Two-step sandwich 

  • Calibration

    2-point

  • Sample material

    Cerebrospinal Fluid (CSF)

  • Sample volume

    30 µL - cobas e 801 module and cobas e 402 module 
    50 µL - cobas e 411 analyzer and cobas e 601/602 modules

  • LoB (Limit of Blank)

    4 pg/mL

  • LoD (Limit of Detection)

    8 pg/mL

  • LoQ (Limit of Quantitation)

    8 pg/mL

  • Measuring range

    8 – 120 pg/mL

  • Reagent onboard-stability

    28 days - cobas e 801 module and cobas e 402 module
    16 weeks - cobas e 411 analyzer and cobas e 601/602 modules

Related articles

...
    ...

    References

    1. Elecsys® β-Amyloid (1-42) CSF II E1G (Mat. No. 08821909500V1.0) method sheet, v1.0  2021-03;  Elecsys® β-Amyloid (1-42) CSF II E2G (Mat. No. 08821941500V1.0) method sheet, v1.0  2021-03; Elecsys® Phospho-Tau (181P) CSF II E1G  (Mat. No. 088466935001.0) method sheet, v1.0  2021-03;  Elecsys® Phospho-Tau (181P) CSF II E2G (Mat. No. 088467155001.0) method sheet, v1.0  2021-03; Elecsys® Total-Tau CSF CSF II E1G (Mat. No.08846634500 1.0) method sheet, v1.0  2021-03; Elecsys® Total-Tau CSF CSF II E2G (Mat. No. 088466855001.0) method sheet, v1.0  2021-03
    2. Rabinovici, G.D. et al. (2019). Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA 321(13), 1286-1294.
    3. Hansson, O. et al. (2018). CSF biomarkers of Alzheimer’s disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement 14(11), 1470-1481
    ...
      ...